Scientists hunt for blood clues to bipolar disorder

NCT ID NCT07434414

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study looked at two specific proteins in the blood of people with bipolar disorder during a manic episode and compared them to healthy volunteers. The goal was to see if these proteins, which are linked to inflammation and brain cell communication, could help explain the condition. 72 people took part, and the researchers measured their blood and mood symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

72 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adult participants aged 18-65 years. The bipolar disorder (BD) group included consecutive patients diagnosed with BD according to DSM-5-TR criteria who were admitted to the psychiatry clinic of Elazığ Mental Health and Diseases Hospital (Turkey). The healthy control (HC) group consisted of individuals from the general population who applied to the hospital medical board and had no current or past psychiatric or significant medical disorders. All participants provided informed consent prior to enrollment.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. For Bipolar Disorder (BD) Group: \*Inclusion Criteria: * Diagnosis of BD according to DSM-5-TR * Acute manic episode * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent For Bipolar Disorder (BD) Group: \* Exclusion Criteria: • Hypertension • Diabetes mellitus • Chronic kidney disease • Rheumatoid arthritis • Systemic lupus erythematosus • Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than BD * Alcohol/drug/substance use 2. For Healthy Control Group: \*Inclusion Criteria: • No psychiatric diagnosis • No systemic or immunological illness * Medication-free for at least one month * Age ≥ 18 years and \< 65 years * Provided informed consent For Healthy Control Group: \*Exclusion Criteria: * Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Having psychiatric disorders * Alcohol/drug/substance use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder (BD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Elazığ Mental Health and Diseases Hospital Psychiatry Clinic

    Elâzığ, Elâzığ, 23200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.